Previous Article | Next Article ![]()
Applied and Environmental Microbiology, February 2009, p. 1144-1155, Vol. 75, No. 4
0099-2240/09/$08.00+0 doi:10.1128/AEM.02518-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
,
Department of Bacteriology, University of Wisconsin—Madison, Madison, Wisconsin 53706,1 Institute of Genomic Sciences and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 212012
Received 3 November 2008/ Accepted 12 December 2008
|
|
|---|
|
|
|---|
A preliminary chemical structure of ZmA was determined by the Handelsman and Clardy groups (18). More recently, Rogers and colleagues performed a series of elegant structural studies that compared ZmA produced from B. cereus with synthetic ZmA derivatives that had varied stereocenters (32, 33). From this work, the chemical structure of ZmA with the appropriate stereocenters has been determined (Fig. 1). The antibiotic has a number of unusual structural components. First, ZmA is one of only a few linear aminopolyol natural products to be identified. Second, the core of ZmA is formed from ethanolamine and glycolyl moieties that are rarely seen in natural products. Third, the N terminus of ZmA is formed from D-serine (D-Ser), not L-Ser, as initially expected. This suggests that the amino acid either is incorporated as the D isomer or is incorporated as the L isomer and is then isomerized at some point during its biosynthesis. Finally, ZmA is the only natural product that we are aware of that contains an unusual 2-aminosuccinamide moiety. This moiety is likely to come from the amino acid β-ureidoalanine (β-Uda) that has had its carboxylic acid replaced by a terminal amide.
![]() View larger version (11K): [in a new window] |
FIG. 1. Chemical structure of ZmA. Numbers have been added to identify the sites of hydroxyl groups as discussed in the text.
|
In addition to the mixed amino acid and carboxylic acid backbone, ZmA also contains a terminal amide (Fig. 1). How these amide groups are formed was investigated by Müller and colleagues and Silakowski and colleagues as they deciphered how myxothiazole is biosynthesized (29, 36). Briefly, the NRPS/PKS megasynthase that assembles the backbone of myxothiazole forms a product that is 1 amino acid longer than myxothiazole. This results in a biosynthetic intermediate that contains a glycyl residue at the C terminus of myxothiazole, while the intermediate remains thioesterified to the peptidyl carrier protein (PCP) domain of the terminal NRPS module. The
-carbon of the glycine is hydroxylated by a flavin-dependent monooxygenase, a modification that results in an unstable intermediate that spontaneously releases the myxothiazole backbone, with the nitrogen of the terminal amide coming from the glycine. The terminal PCP domain contains the glyoxyl group left after C-N bond cleavage, and this product is released from the PCP domain by the neighboring thioesterase (Te) domain. Based on this precedent, the terminal amide of ZmA may be produced by a similar mechanism.
Here, we present the identification of the complete ZmA biosynthesis gene cluster from B. cereus UW85. The biosynthesis gene cluster was identified by locating the previously reported biosynthesis genes and by mapping the locations of transposon insertions that abolished the ability of B. cereus UW85 to produce ZmA. As expected, the gene cluster codes for NRPS and PKS enzymology that is likely to be involved in ZmA assembly from its amino acid and carboxylic acid precursors. Surprisingly, we fiound that ZmA not only is likely to be processed at its C terminus to generate the terminal amide by a mechanism similar to that seen in myxothiazole biosynthesis, but it appears to also be processed at its N terminus. These two processing events potentially lead to the biosynthesis of two additional metabolites besides ZmA. Furthermore, the kanosamine biosynthesis gene cluster appears to be fully contained within the ZmA biosynthesis gene cluster. A mechanism for ZmA production is presented, along with proposals for how three additional metabolites are produced by the enzymes encoded by this unusual gene cluster.
|
|
|---|
65 kb), and as such, we could not examine if the gene cluster could confer the ZmA production phenotype independently of any other genomic factors.
Generation of A domain overproduction clones.
PCR-based cloning was used to introduce the DNA coding for each adenylation (A) domain into an Escherichia coli expression vector. The primers used for PCR amplification are shown in Table 1. Each set of the PCR primers was designed with an NheI recognition site in the primer at the 5' end of the gene and a SalI recognition site in the primer at the 3' end of the gene. The amplicons were cloned into the corresponding restriction sites of the pET28b vector (Novagen, Madison, WI). The correct sequence for each cloned gene was verified by sequencing at the University of Wisconsin Biotechnology Sequencing Center (Madison, WI). Each overexpression vector produced a protein with an N-terminal hexahistidine tag that was used for affinity purification.
|
View this table: [in a new window] |
TABLE 1. Primers used for PCR amplification of NRPS genes
|
10 g of cells (wet weight), which were resuspended in 20 ml of protein purification buffer. The cell suspension was sonicated (Fisher 550 Sonic Dismembrator; power = 5; 15 min of sonication with 1 s on, 1 s off), and the cell debris was removed by centrifugation (30 min at 15,000 rpm; Beckman J2-21 centrifuge; Beckman JA-25.50 rotor) at 4°C. Imidazole (5 mM final concentration) was added to the cleared lysate, and the lysate was then incubated with 1 ml of Ni-nitrilotriacetic acid resin (Qiagen) for 1 h with gentle rocking. The resin was applied to a column, and protein was eluted using a step gradient with 5 ml of protein purification buffer containing increasing concentrations of imidazole (20, 40, 60, 100, and 250 mM). The elutions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Coomassie blue staining, and elutions containing pure recombinant protein were combined and dialyzed for 16 h at 4°C in dialysis buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 10% [vol/vol] glycerol). After dialysis, the protein concentration was determined spectrophotometrically at A280 by use of the calculated molar extinction coefficients: ZmaB-A1, 72,825 M–1 cm–1; ZmaB-A2, 97,320 M–1 cm–1; ZmaK-A, 57,885 M–1 cm–1; ZmaO-A, 40,865 M–1 cm–1; ZmaQ-A1, 56,075 M–1 cm–1; and ZmaQ-A2, 50,240 M–1 cm–1. The proteins were flash-frozen in liquid nitrogen and stored at –80°C until they were used.
dATP-32PPi exchange assays for aminoacyl-AMP formation.
Each purified enzyme containing an A domain was analyzed for amino acid-dependent dATP-32PPi exchange using standard protocols (30, 43). Briefly, exchange assays were conducted for each amino acid individually in a reaction mixture (100 µl) containing 500 µM of the amino acid to be tested, 75 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 5 mM dithiothreitol, 3.5 mM dATP, 1 mM 32PPi (2.15 Ci/mol; Perkin-Elmer), and 1 µM enzyme. The A domains of NRPSs are not selective against dATP, in contrast to other adenylyltransferases (30); therefore, we substituted dATP for ATP in these reactions to ensure we were analyzing A domain-catalyzed exchange and not exchange catalyzed by other adenylyltransferase enzymes, such as tRNA synthetases. The reaction mixtures were incubated at 23°C for 30 min. The reactions were stopped by the addition of a quench solution containing 3.5% (vol/vol) perchloric acid, 100 mM Na-PPi, and 1.6% (wt/vol) activated charcoal. The charcoal pellets were washed twice with quenching buffer lacking charcoal before being counted in a scintillation counter. Assays with each enzyme were performed two or more times for each amino acid. The results are reported as percentages of maximum substrate activation.
ZmA purification from B. cereus AH1134.
One-liter cultures of 0.5x tryptic soy broth were inoculated with 1 ml of a saturated overnight B. cereus AH1134 culture and grown at 30°C for 3 days. The cells were removed by centrifugation (10 min at 7,000 rpm; Beckman J2-21 centrifuge; Kompspin KA-9 rotor), and the culture supernatant was retained. The pH of the supernatant was adjusted to pH 7.0 with HCl and batch bound to 15 ml of Amberlite IRC-50 ion-exchange resin (Acros Organics) preequilibrated with 5 mM NH4PO4, for 1 h at 23°C. The resin was applied to a chromatography column and washed with 10 bed volumes of 5 mM NH4PO4. ZmA was eluted from the column with 5 ml of increasing concentrations of NH4OH (250 mM, 500 mM, and 1 M). The elutions were flash frozen in liquid nitrogen and lyophilized for 2 days. The lyophilized material was resuspended in H2O and neutralized to pH 7.0 with HCl.
ZmA analysis by HPLC and MALDI-TOF MS.
Authentic ZmA and samples purified from B. cereus AH1134 were analyzed by high-performance liquid chromatography (HPLC). The samples were separated on a Vydac SP C18 silica column on a Beckman-Coulter Gold system with a 1-ml/min flow rate. Buffer A was H2O-0.1% trifluoroacetic acid (TFA), and buffer B was acetonitrile-0.1% TFA. The separation profile was 5 min of isocratic development at 100% A-0% B and a linear gradient over 15 min to 20% acetonitrile plus 0.1% TFA. Metabolite elution was monitored at 210 nm. The metabolite corresponding to ZmA was collected and analyzed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) on a Voyager-DE Pro Workstation (PerSeptive Biosystems). The MALDI-TOF MS data were calibrated with peptides of known mass during each analysis.
Nucleotide sequence accession number.
The gene cluster identified in this study has been submitted to GenBank under accession number FJ430564.
|
|
|---|
![]() View larger version (11K): [in a new window] |
FIG. 2. ZmA biosynthesis gene clusters from B. cereus UW85 (top) and B. cereus AH1134 (bottom). For the B. cereus UW85 gene cluster, the genes labeled zma are proposed to be involved in ZmA biosynthesis and those labeled kab are proposed to be involved in kanosamine biosynthesis. Due to space limitations, some of the genes have been abbreviated (e.g., C is equivalent to zmaC). The triangles identify Tn5401 insertion sites that result in the loss of ZmA production, with the exception of UW85 orf2, which identifies a deletion mutant that was previously constructed. The labeling of the insertion sites uses the mutant strain numbering previously described (12). The H28 arrow denotes the location of the promoter that is induced in the presence of P. aureofaciens (11). For the B. cereus AH1134 gene cluster, the number above each ORF identifies the locus tag. The locus tags have been abbreviated due to space limitations (e.g., C0218 is equivalent to BCAH1134_C0218, while 20 is equivalent to BCAH1134_C0220). The genes from B. cereus AH1134 are shown immediately below their homologs from B. cereus UW85. The genes are color coded based on their established or proposed functions: red, NRPS- or PKS-associated genes; blue, ACP-linked PKS extender unit biosynthesis; orange, ZmA resistance; yellow, ZmA processing; gray, kanosamine biosynthesis; and green, β-Uda biosynthesis.
|
Additional support for this conclusion comes from work that has analyzed ZmA production in B. thuringiensis strains (35, 49, 50). Shao and colleagues recently constructed a deletion of a homolog of zmaC in the ZmA-producing bacterium B. thuringiensis GO3 (35). The resulting strain was no longer able to produce ZmA, confirming that this ZmaC homolog plays a role in antibiotic biosynthesis. Additionally, Zhao and colleagues constructed strains of B. thuringiensis subsp. kurstaki strain YBT-1520 with homologs of zmaU, zmaV, and zmaQ deleted, and these strains also lost the ability to produce ZmA (49, 50). Based on the similarity of the genes from these B. thuringiensis strains and those we identified in B. cereus UW85 (97 to 100% identity) and the close evolutionary relationship between the two species (46), it was reasonable to expect that similar results would be observed in B. cereus UW85.
The identification of the ZmA biosynthesis gene cluster also provided new insights into environmental cues that induce ZmA production. Previous work investigated the genome of B. cereus UW85 for promoters that are induced when the bacterium is exposed to the plant-associated bacterium Pseudomonas aureofaciens (11). The influence of this Pseudomonas species on B. cereus UW85 gene expression was investigated due to both bacteria being isolated from the same plant root segments (11). One of the B. cereus UW85 promoters that is induced in the presence of P. aureofaciens is carried on the clone H28. The promoter from this clone is immediately upstream of a gene that at the time had no known function. We reanalyzed this promoter in comparison to the genes of the ZmA biosynthesis gene cluster and determined the promoter was immediately upstream of zmaA. Thus, one of the natural inducers of the ZmA biosynthesis gene cluster in B. cereus UW85 is a common inhabitant of the same plant root environment.
Analysis of B. cereus AH1134 for ZmA production.
During our analysis of the genes and associated proteins in the ZmA biosynthesis gene cluster, it was noticed that a nearly identical gene cluster (genes showing 97 to 100% identity) is present in the genome of B. cereus AH1134 (Fig. 2). This finding suggested that B. cereus AH1134 was capable of producing ZmA. To test this possibility, we analyzed the supernatant of a sporulated culture of B. cereus AH1134 for the presence of ZmA. A metabolite with the same elution time from HPLC as an authentic sample of ZmA was identified (Fig. 3), and it also had the same UV-visible spectrum (data not shown). This metabolite was collected from the HPLC and analyzed by MALDI-TOF MS, and the metabolite had a mass consistent with that of ZmA (calculated m/z, [M + H]+ = 397.2, [M + Na]+ = 419.2, [M + K]+ = 435.2; observed m/z, [M + H]+ = 397.0, [M + Na]+ = 419.0, [M + K]+ = 435.1). These data support the hypothesis that B. cereus AH1134 produces ZmA.
![]() View larger version (14K): [in a new window] |
FIG. 3. Representative HPLC traces of authentic ZmA (trace A) and metabolites purified from B. cereus AH1134 (trace B). The absorption peak associated with ZmA from the authentic sample is identified. The metabolites eluting with corresponding absorption peaks in trace B were collected and analyzed by MALDI-TOF MS. The y axis represents milliabsorbance units at 210 nm.
|
In further support of this conclusion, these genes are similar to five genes from B. subtilis that have been shown to be involved in the production of the amino sugar antibiotic 3,3'-neotrehalosadiamine (20). This antibiotic has not been detected in cultures of B. cereus UW85, but it is known that the bacterium produces the amino sugar kanosamine (Fig. 4). The relevance of this is that 3,3'-neotrehalosadiamine is a dimer of kanosamine monomers. Based on this, we propose that the five genes between zmaS and zmaT are involved in the regulation, biosynthesis, and export of kanosamine from B. cereus UW85; thus, we have used kab to denote the genes we propose to be involved in kanosamine biosynthesis (Fig. 2 and Table 2). A simple three-step pathway from UDP-glucose to kanosamine can be developed based on the sequence similarities of KabA, -B, and -C to enzymes with known functions (Fig. 4). Further analysis will be required to determine whether these genes are involved in 3,3'-neotrehalosadiamine or kanosamine biosynthesis. In any case, the lack of these genes in B. cereus AH1134 did not disrupt its ability to produce ZmA, allowing us to conclude that the kabRABCD genes are not directly involved in ZmA production in B. cereus UW85.
|
View larger version (8K): [in a new window] |
FIG. 4. Proposed pathway for the biosynthesis of kanosamine.
|
|
View this table: [in a new window] |
TABLE 2. Predicted proteins involved in kanosamine production
|
(i) Biosynthesis of ZmA precursors.
We proposed that ZmA biosynthesis would involve the condensation of five precursors (12). Two of these precursors, L-Ser and malonyl-CoA, would be readily available for ZmA biosynthesis due to their being common primary metabolites. The three remaining precursors would be unique to ZmA biosynthesis and would require specific enzymes for their formation. We had previously established that ZmaG, ZmaD, ZmaE, and ZmaN produce the precursor (2R)-hydroxymalonyl-ACP (Fig. 5A and Table 3), while the concerted actions of ZmaG, ZmaH, ZmaI, and ZmaJ form the precursor (2S)-aminomalonyl-ACP (Fig. 5B and Table 3) (4). We also proposed that L-Dap was a potential precursor for ZmA based on the amino acid being incorporated into the antibiotics viomycin and capreomycin (12, 14, 44). Consistent with this hypothesis, homologs of the enzymes proposed to generate L-Dap for viomycin (44) and capreomycin (14) biosynthesis are encoded by the ZmA biosynthesis gene cluster. These enzymes, ZmaU and ZmaV, are proposed to cooperatively catalyze the formation of L-Dap from L-Ser or O-acetyl-L-Ser and an amino group donor, such as L-ornithine (Fig. 5C; Table 3). Zhao and colleagues recently showed that deleting homologs of zmaV and zmaU from the genome of B. thuringiensis subsp. kurstaki strain YBT-1520 resulted in a strain that would not produce ZmA unless L-Dap was added to the culture medium (50). This supports our initial hypothesis that this amino acid is required for ZmA biosynthesis. However, these data did not eliminate the possibility that β-Uda, the amino acid that forms the terminal amide of ZmA, was the true precursor for incorporation into ZmA by the hybrid NRPS/PKS. The nonproteinogenic amino acid β-Uda would arise from the carbamoylation of L-Dap by ZmaT (Fig. 5C and Table 3).
![]() View larger version (24K): [in a new window] |
FIG. 5. Schematic of the ZmA precursor biosynthesis pathways. (A) Formation of (2R)-hydroxymalonyl-ACP. (B) Formation of (2S)-aminomalonyl-ACP. (C) Formation of L-Dap and β-Uda. Carb P, carbamoylphosphate; PLP, pyridoxal phosphate.
|
|
View this table: [in a new window] |
TABLE 3. Predicted proteins involved in ZmA production
|
(iii) NRPSs involved in ZmA biosynthesis.
The structure of ZmA suggests that two NRPS modules are required to incorporate the amino acids on either side of the central polyketide core. Consistent with this hypothesis, the N terminus of ZmaK contains an NRPS module and the C terminus of ZmaA contains a C domain of NRPSs. NRPS modules contain the necessary catalytic domains to recognize and incorporate an amino acid into a natural-product backbone, while a C domain is the portion of an NRPS module that catalyzes amide bond formation between two amino acids tethered to neighboring PCP domains (reviewed in reference 13). These observations suggest that an amino acid will be introduced before and after the PKS components discussed above (Table 4). The unusual aspect of the NRPS module of ZmaK is that it contains a C domain at the N terminus, suggesting that an amino acid is condensed to the first amino acid of ZmA. Additionally, when we analyzed the remaining ORFs in the ZmA gene cluster, we identified not just one NRPS module to incorporate the final amino acid, but four additional NRPS modules contained on ZmaB, ZmaC, ZmaO, and ZmaQ (Table 4). These observations suggested that ZmA biosynthesis is more complicated than is implied by its chemical structure.
|
View this table: [in a new window] |
TABLE 4. NRPS and PKS components encoded by the biosynthesis gene cluster
|
![]() View larger version (19K): [in a new window] |
FIG. 6. (A) Analysis of purified proteins using 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis stained with Coomassie blue. (B to G) Representative amino acid-dependent dATP-32PPi exchange reactions using purified proteins and amino acids.
|
We note that our data on ZmaQ are not consistent with data recently published by Zhao and colleagues (50). In their study, Zhao and colleagues analyzed the second A domain of a homolog of ZmaQ and presented data showing that it activated L-Dap, but at only slightly higher levels than L-Ser, L-Cys, and L-Ala. They did not test any other amino acids. Based on their results, they proposed that this A domain is the one that incorporates L-Dap into the ZmA structure. However, it is not clear what role the first module of ZmaQ would then play. We took the approach that there were clearly too many A domains for the incorporation of only L-Ser and L-Dap into ZmA; thus, we needed to test activation with more amino acids than just those seen in the ZmA structure. The second A domain of ZmaQ clearly preferred L-Met over L-Dap (Fig. 6G). In fact, we failed to detect any A domain that preferred L-Dap over other amino acids. However, we did find that ZmaB-A1 is specific for β-Uda, which is carbamoylated L-Dap (Fig. 6B). Therefore, from our analysis of the NRPS components of the ZmA biosynthesis pathway, L-Dap is not a precursor used by the NRPS components for ZmA biosynthesis. Instead, L-Dap is carbamoylated first by ZmaT to generate β-Uda (Fig. 2), and this is the amino acid incorporated by the NRPS.
Finally, ZmaC is an NRPS component with unusual domain architecture. The protein has three domains, with the second and third domains showing sequence similarity to PCP and C domains, respectively. The N-terminal domain of ZmaC is homologous to the C39A subfamily of C39 cysteine peptidases. This subfamily of peptidases is commonly involved in the processing of bacteriocin antibiotics by cleaving the leader peptide from the antibiotics as they are exported out of the cell (2, 10). While the N-terminal domain of ZmaC is homologous to these types of peptidases, the domain does not contain all of the essential catalytic residues. ZmaC contains the conserved His residue that is part of the catalytic diad and the Gln residue that contributes to the oxyanion hole that stabilizes the enzyme intermediate. However, ZmaC lacks the catalytic Cys residue that functions as the attacking nucleophile and site of the covalently linked acyl intermediate. This suggests that the domain is not functioning as a protease but rather plays some other role in ZmA biosynthesis. A potential role for the domain is discussed in more detail below.
Proposal for the biosynthesis of ZmA and two additional metabolites.
The bioinformatics and biochemistry discussed above provided a summary of all the likely catalytic steps that are involved in ZmA assembly. The next issue was to generate a scheme for how all of these enzymes work coordinately to generate the antibiotic.
(i) Functional order of the PKS and NRPS components.
As discussed above, the order in which the PKS components function during ZmA biosynthesis is straightforward, with the C terminus of ZmaK incorporating malonyl-CoA and the concerted actions of ZmaF and ZmaA incorporating (2S)-aminomalonyl-ACP and (2R)-hydroxymalonyl-ACP (Fig. 7A). The next issue was to determine how the NRPS components are coordinated around the PKS components. With the identity of the amino acids activated by each of the A domains defined by biochemical analysis, it is possible to place ZmaB immediately downstream of ZmaA. This is based on the finding that the first A domain of ZmaB activates β-Uda, the amino acid tethered to the glyoxyl moiety incorporated by the C-terminal PKS module of ZmaA (Fig. 7A). ZmaQ can be placed as the final component of the megasynthase because it contains a C-terminal Te domain. These domains are well characterized and catalyze release of the nonribosomal peptide or polyketide from the megasynthase as the final step in synthesis (24).
![]() View larger version (43K): [in a new window] |
FIG. 7. Proposed biosynthesis scheme for the production of ZmA and two additional metabolites (metabolites A and B). The solid bars at the top of panel A identify the 10 different NRPS or PKS modules (M1 to M10). Modules M1 to M7 are involved in the incorporation of L-Asn, L-Ser, malonate, (2S)-aminomalonate, (2R)-hydroxymalonate, β-Uda, and L-Ala, respectively, while modules M9 and M10 incorporate L-Ile and L-Met, respectively. Each circle represents a catalytic domain of the NRPS or PKS component. C, condensation; A, adenylation; E, epimerization; KS, ketosynthase; KR, ketoreductase; Pr, C39A protease. The NRPS and PKS modules and the precursors they incorporate have been color coded to reflect the metabolite(s) they are involved in producing (green, metabolite A; red, ZmA; blue, metabolite B). The enzymes ZmaL and ZmaM are represented by orange and purple ovals, respectively, and are located at the sites of their proposed functions.
|
-amino group of the first amino acid of a lipopeptide. This strongly suggests the N terminus of ZmA initially contained a fatty acid, along with D-Asn. Finally, Chiocchini and colleagues and Hahn and Stachelhaus have shown that E domains and C domains that interact with each other contain communication domains that function as sites of specific protein-protein interactions between E and C domains on different NRPS polypeptides (7, 15, 16). Analysis of the C terminus of the E domain of ZmaO and the N terminus of ZmaK identified sequences consistent with communication domains (data not shown). This supports our contention that ZmaO functions immediately prior to ZmaK. Based on these analyses, ZmaC is proposed to function between ZmaB and ZmaQ to complete the NRPS/PKS megasynthase organization (Fig. 7A).
(ii) ZmA biosynthesis and processing.
The analysis of the NRPS/PKS megasynthase strongly suggested that ZmA was biosynthesized as part of a larger molecule that was processed during its biosynthesis. Based on our analysis of the NRPS/PKS components and the other enzymes encoded by the biosynthesis gene cluster, the following biosynthesis scheme is proposed. ZmaO activates L-Asn, condenses it with a fatty acid, and epimerizes the L-Asn to D-Asn to form the fatty acyl-D-Asn-S-ZmaO intermediate (Fig. 7B). The next five NRPS/PKS modules form the backbone of ZmA by condensing the fatty acyl-D-Asn intermediate with L-Ser, malonylate, (2S)-aminomalonate, (2R)-hydroxymalonylate, and β-Uda (Fig. 7B). It is expected that at some point during the condensation of these precursors, the stereochemistry of the L-Ser residue is changed to D-Ser to account for the stereochemistry in the final product. It is not yet clear how this occurs, because an epimerase (E) domain is not found in the NRPS module that incorporates L-Ser. However, the module immediately upstream of the L-Ser-associated module contains an E domain. One possibility is that this domain catalyzes the epimerization of L-Ser, as well as L-Asn. Another possibility is that the C domain associated with L-Ser is involved in this conversion. This C domain does not cluster with type II C domains as would be expected of a C domain associated with an upstream E domain (see Fig. S1 in the supplemental material). Potentially this C domain has an additional epimerase function analogous to that observed with bifunctional C/E domains (1). Further analysis of ZmA biosynthesis will be required to differentiate between these hypotheses.
The finding of an additional NRPS module on ZmaB suggests the growing fatty acyl-peptide/polyketide is extended by an additional amino acid, L-Ala, to form a covalently linked intermediate on the second PCP domain of ZmaB (Fig. 7C). At this stage, the backbone of ZmA has a fatty acyl-D-Asn at its N terminus and L-Ala at its C terminus, both of which must be removed to make the antibiotic. Insights into the processing at the C terminus come from the work of Müller and colleagues on the formation of the terminal amide of the natural product myxothiazole, as discussed above. Using the same logic, the L-Ala introduced onto the C terminus of the ZmA backbone would be hydroxylated to release a ZmA derivative containing a terminal amide, leaving a pyruvyl-S-PCP intermediate tethered to the second PCP domain of ZmaB (Fig. 7D). The enzyme that would catalyze this hydroxylation is ZmaL, a protein that shows sequence similarity to flavin-dependent monooxygenases (Table 3).
There are two issues for ZmA that still need to be addressed. First, the pyruvyl moiety must be removed from the NRPS to allow additional turnovers of the NRPS/PKS megasynthase. Second, the N-terminal fatty acyl-D-Asn moiety must be removed from the N terminus of ZmA. The removal of the pyruvyl moiety is likely to be accomplished by the continued transfer of the PCP-tethered intermediate down the NRPS/PKS megasynthase. The first step in this process is the transfer of the pyruvyl moiety from ZmaB to the PCP domain of ZmaC by the N-terminal C39A peptidase domain of ZmaC. As stated previously, this domain lacks the active-site cysteine but retains the histidine residue for deprotonation of a thiol and the glutamine residue to stabilize the oxyanion intermediate for this class of cysteine proteases. We propose that the thiol from the PCP domain of ZmaC replaces the active-site cysteine thiol, resulting in the domain catalyzing a thiol exchange of the pyruvyl moiety from the PCP domain of ZmaB to the PCP of ZmaC (Fig. 7D). This is then condensed with the L-Leu and L-Met residues tethered to ZmaQ (Fig. 7E), with the Te domain of ZmaQ releasing "metabolite B" from the megasynthase (Fig. 7F). It is not clear at this time what role this metabolite might play in B. cereus physiology.
The fatty acyl-D-Asn-ZmA intermediate released from the NRPS/PKS megasynthase by the action of the ZmaL-catalyzed hydroxylation must also be processed to generate ZmA. The only candidate enzyme encoded by the biosynthesis gene cluster to catalyze such a peptidase activity is ZmaM. The C terminus of ZmaM is homologous to ABC-type transporters involved in metabolite efflux, while the N terminus is homologous to β-lactamases and D-alanyl-D-alanine carboxypeptidases (Table 3). Thus, we propose that as the acyl-D-Asn-ZmA is exported out of the cell through ZmaM, the N terminus of this transporter cleaves the metabolite between the D-Asn and D-Ser, releasing ZmA and the fatty acyl-D-Asn (Fig. 7F, metabolite A). We cannot eliminate the possibility that some other endogenous peptidase catalyzes this cleavage. We are currently analyzing the culture supernatants of B. cereus UW85 for the presence of the predicted metabolites A and B.
The three remaining enzymes encoded by the ZmA biosynthesis gene cluster have functions in resistance or are likely to be involved in forming functional NRPS/PKS components and keeping these components functional. ZmaR has been shown to be the ZmA resistance enzyme that catalyzes the N-acetylation of the
-amino group of the D-Ser moiety of ZmA (41). ZmaS is a homolog of phosphopantethenyltransferases that catalyze the conversion of carrier proteins (ACPs and PCPs) from their apoforms to holoforms by transferring the 4'-phosphopantetheinyl moiety of CoA to a conserved serine of the carrier proteins (47). ZmaP is a homolog of type II Tes that are involved in proofreading the NRPS/PKS megasynthases to ensure stalled intermediates are removed (19, 21, 34). It is reasonable to propose that ZmaP performs similar proofreading functions during ZmA biosynthesis.
Conclusions.
We have presented genetic, bioinformatics, and biochemical evidence in support of our hypothesis that we have identified the ZmA biosynthesis gene cluster in B. cereus UW85. We have also provided evidence that B. cereus AH1134 produces ZmA and have identified the putative biosynthesis gene cluster in the bacterium. We have provided molecular evidence that ZmA is biosynthesized in an unusual manner that involves processing of both its N and C termini, potentially resulting in the production of two additional metabolites besides ZmA (Fig. 7). Finally, we propose that the gene cluster identified in B. cereus UW85 also codes for enzymes involved in the biosynthesis of the antibiotic kanosamine.
This work was supported in part by the National Institutes of Health (AI065850) and by an Alfred Toepfer Faculty Fellow award to M.G.T.
Published ahead of print on 19 December 2008. ![]()
Supplemental material for this article may be found at http://aem.asm.org/. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»